Calgary Transit Is En-Route With Access-IS Ticket Validators
27.10.2020 12:00:00 EET | Business Wire | Press release
Access-IS, part of HID, the leading supplier of software agnostic ticket validators is excited to announce the integration of its VAL100 devices by Masabi. The integration is part of Masabi’s My Fare solution, a contactless mobile ticketing app for Calgary Transit that lets passengers buy tickets and passes anytime, anywhere, using their smartphones. It’s fast, easy, contactless and a safe way to pay and ride transit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005015/en/
Access-IS VAL100 ticket validator alongside Masabi’s My Fare solution (Photo: Business Wire)
The My Fare app, which is powered by Masabi’s Justride platform and can be downloaded from the App Store and Google Play, allows riders of Calgary Transit services to purchase and use fare products such as regular monthly and day passes, airport boarding pass, and single ride tickets directly from their mobile device.
As part of the project over 1000 Access-IS VAL100 ticket validators have been installed across the bus network covering 155 routes. Passengers scan their dynamic and encrypted mobile passes on the devices when boarding the bus, with an audible beep and a colored screen identifying the ticket as valid for use. These validation units will help speed up boarding times making riding Calgary Transit services faster and safer by enabling contactless fare payment and validation. The validation units are powered by Masabi’s Justride Inspect software but also read NFC and contactless EMV (cEMV) technology, giving the agency the flexibility to turn on Account-Based Ticketing and other account-based tokens, if required.
“Calgarians, like citizens in towns and cities around the world, are using smartphones in almost all aspects of their day and made offering the option for riders to use their phone instead of a paper ticket a logical step for Calgary Transit,” said Brian Zanghi, CEO of Masabi. “The change in people’s behaviour brought about by the current requirement for social distancing has made mobile ticketing and the move towards a more contactless journey experience a must-have for transit agencies.”
The VAL100 combines barcode and NFC/RFID reading functionality to provide a single point of presentation for tickets and travel passes – whether presented on a paper ticket, smartcard or mobile phone. It is also available with EMV Level 2 certification, allowing for applications where contactless payments are required. It offers PCI and SRED compliance for contactless payments using VISA, MasterCard, AMEX and Discover payment schemes. It features clear visual and audio passenger feedback, a robust design and a wide range of connection options for installation flexibility.
Speaking about the installation, Bryan Cunningham Regional Sales Manager (Americas) at Access-IS said “It’s always a pleasure to work with Masabi to deliver a ticketing and fare payment solution focused on providing the very best passenger experience whilst protecting the transits agency’s ability to manage fare revenue.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005015/en/
Contact information
Andrew Covey
+44(0)118-966-3333
Andrew.Covey@access-is.com
www.access-is.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom